Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Craig T. Jordan

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-8165
    Other Positions
    TitleDivision Head
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOM-MED
    DivisionHematology


    Collapse Overview 
    Collapse overview
    Dr. Jordan completed his bachelor’s degree at the University of California, Berkeley, followed by doctoral studies at Princeton University with a focus on the molecular biology of hematopoietic stem cells. He then went on to perform post-doctoral studies at the Whitehead Institute. He next spent several years working in the biotechnology industry before rejoining the academic ranks in 1997 at the University of Kentucky as an Assistant Professor of medicine. In 2003 he moved to the University of Rochester, where he became the Director of Translational Research for Hematologic Malignancies at the James P. Wilmot Cancer Center. In 2013 he was recruited to his present position, Chief of the Hematology Division at the University of Colorado Denver Medical Center.

    Collapse Research 
    Collapse research activities and funding
    R35CA242376     (JORDAN, CRAIG T.)Sep 8, 2020 - Aug 31, 2027
    NIH
    Therapeutic Targeting of Human AML Stem Cells
    Role: Principal Investigator
    I01BX004768     (JORDAN, CRAIG T.)Apr 1, 2020 - Mar 31, 2025
    NIH
    Therapeutic Targeting of MDS Stem Cells
    Role: Principal Investigator
    R01CA243452     (JORDAN, CRAIG T.)Dec 1, 2019 - Nov 30, 2020
    NIH
    Metabolic mechanisms of venetoclax resistance in acute myeloid leukemia stem cells
    Role: Principal Investigator
    T32CA236734     (JIMENO, ANTONIO)Jul 8, 2019 - Jun 30, 2025
    NIH
    Cancer Immunotherapy and Experimental Therapeutics - T32
    Role: Co-Principal Investigator
    R01CA220986     (JORDAN, CRAIG T.)Dec 6, 2017 - Nov 30, 2022
    NIH
    Microenvironment-induced metabolic plasticity in leukemia stem cells
    Role: Principal Investigator
    R01CA200707     (JORDAN, CRAIG T.)Jul 1, 2016 - Jun 30, 2021
    NIH
    Characterization and targeting of leukemia stem cell metabolism
    Role: Principal Investigator
    R01CA166265     (JORDAN, CRAIG T.)Jun 1, 2012 - May 31, 2018
    NIH
    Oncogene Cooperativity in Leukemia Stem Cells
    Role: Principal Investigator
    S10RR023458     (JORDAN, CRAIG T.)Sep 30, 2007 - Sep 29, 2008
    NIH
    Amnis ImageStream Flow Cytometer
    Role: Principal Investigator
    R01CA122206     (JORDAN, CRAIG T.)Aug 14, 2007 - Jul 31, 2011
    NIH
    Selective in vivo Ablation of Leukemia Stem Cells
    Role: Principal Investigator
    R01CA090446     (JORDAN, CRAIG T.)Jan 16, 2002 - Dec 31, 2007
    NIH
    Cellular and Molecular Studies of Leukemic Stem Cellss
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Schlein LJ, Brill SA, Brady RV, Farrell KB, Rose BJ, Meuten TK, Jordan CT, Thamm DH. Parthenolide As a Therapeutic for Disseminated Canine Neoplasms. J Pharmacol Exp Ther. 2024 02 15; 388(3):774-787. PMID: 38135509.
      View in: PubMed
    2. Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, Jordan CT, Pollyea DA. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. Haematologica. 2023 Dec 14. PMID: 38105738.
      View in: PubMed
    3. Sheth AI, Engel K, Tolison H, Althoff MJ, Amaya ML, Krug A, Young T, Pei S, Patel SB, Minhajuddin M, Winters A, Miller R, Shelton I, St-Germain J, Ling T, Jones C, Raught B, Gillen A, Ransom M, Staggs S, Smith CA, Pollyea DA, Stevens BM, Jordan CT. Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium. bioRxiv. 2023 Oct 03. PMID: 37873284.
      View in: PubMed
    4. Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023 10 01; 108(10):2616-2625. PMID: 37051756.
      View in: PubMed
    5. Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, Liu L, Liu J, Brunetti TM, Engel K, Staggs S, Showers W, Sheth AI, Amaya ML, Minhajuddin M, Winters A, Patel SB, Tolison H, Krug AE, Young TN, Schowinsky J, McMahon CM, Smith CA, Pollyea DA, Jordan CT. A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. Cancer Discov. 2023 09 06; 13(9):2032-2049. PMID: 37358260.
      View in: PubMed
    6. Culp-Hill R, Stevens BM, Jones CL, Pei S, Dzieciatkowska M, Minhajuddin M, Jordan CT, D'Alessandro A. Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2. Metabolites. 2023 Mar 24; 13(4). PMID: 37110126.
      View in: PubMed
    7. Park HJ, Gregory MA, Zaberezhnyy V, Goodspeed A, Jordan CT, Kieft JS, DeGregori J. Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation. Elife. 2022 10 19; 11. PMID: 36259537.
      View in: PubMed
    8. Dong Q, Xiu Y, Wang Y, Hodgson C, Borcherding N, Jordan C, Buchanan J, Taylor E, Wagner B, Leidinger M, Holman C, Thiele DJ, O'Brien S, Xue HH, Zhao J, Li Q, Meyerson H, Boyce BF, Zhao C. HSF1 is a driver of leukemia stem cell self-renewal in acute myeloid leukemia. Nat Commun. 2022 10 16; 13(1):6107. PMID: 36245043.
      View in: PubMed
    9. Islam N, Reuben JS, Dale J, Gutman J, McMahon CM, Amaya M, Goodman B, Toninato J, Gasparetto M, Stevens B, Pei S, Gillen A, Staggs S, Engel K, Davis S, Hull M, Burke E, Larchick L, Zane R, Weller G, Jordan C, Smith C. Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine. JCO Clin Cancer Inform. 2022 09; 6:e2200030. PMID: 36194842.
      View in: PubMed
    10. Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, Gutman JA. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax?+?Azacitidine Versus Intensive Chemotherapy. Transplant Cell Ther. 2022 10; 28(10):694.e1-694.e9. PMID: 35902048.
      View in: PubMed
    11. Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, Abel M, Agarwal A, Avaylon S, Benton E, Blucher A, Borate U, Braun TP, Brown J, Bryant J, Burke R, Carlos A, Chang BH, Cho HJ, Christy S, Coblentz C, Cohen AM, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Dibb J, Eide CA, English I, Hagler S, Harrelson H, Henson R, Ho H, Joshi SK, Junio B, Kaempf A, Kosaka Y, Laderas T, Lawhead M, Lee H, Leonard JT, Lin C, Lind EF, Liu SQ, Lo P, Loriaux MM, Luty S, Maxson JE, Macey T, Martinez J, Minnier J, Monteblanco A, Mori M, Morrow Q, Nelson D, Ramsdill J, Rofelty A, Rogers A, Romine KA, Ryabinin P, Saultz JN, Sampson DA, Savage SL, Schuff R, Searles R, Smith RL, Spurgeon SE, Sweeney T, Swords RT, Thapa A, Thiel-Klare K, Traer E, Wagner J, Wilmot B, Wolf J, Wu G, Yates A, Zhang H, Cogle CR, Collins RH, Deininger MW, Hourigan CS, Jordan CT, Lin TL, Martinez ME, Pallapati RR, Pollyea DA, Pomicter AD, Watts JM, Weir SJ, Druker BJ, McWeeney SK, Tyner JW. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022 08 08; 40(8):850-864.e9. PMID: 35868306.
      View in: PubMed
    12. Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, Minhajuddin M, Winters A, Furtek SL, Gamboni F, Stevens B, D'Alessandro A, Pollyea DA, Reigan P, Jordan CT. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022 01 27; 139(4):584-596. PMID: 34525179.
      View in: PubMed
    13. Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA, Pollyea DA. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021 12 28; 5(24):5565-5573. PMID: 34610123.
      View in: PubMed
    14. Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, Abbott D, Smith CA, Gutman JA. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant. 2022 02; 57(2):160-166. PMID: 34645926.
      View in: PubMed
    15. Shafi SQ, Brown S, Khaw RA, Hirniak J, Burke JR, Giwa L, Marson L, Hill A, Lobo D, Glasbey JC, McLean KA, Patel T, Liu G, Singal A, Nam R, Kathiravelupillai A, Chia WL, Ooi SZY, Matthews M, Ponniah SH, Komor J, Heyes A, Tushingham S, Hettiarachchi DS, K T, Gaier S, Jordan C, Joyce A, Johnston E, Valentine K, Nagassima K, Reis RD, O'Sullivan M, Tittawella A, Geary E, Thorpe C, Jalal AHB, Georgi M, Mergo A, Ramsay E, Sheikh J, Ashok A, Lee KS, Risquet R, Kathiravelupillai S, Chia D, Al Majid S, Matloob Ahmad AE, Hounat A, Shafi S, Wang J, Cambridge WA, Kawar L, Maseland T, Sharma K, Moses J, Patsalides MA, Brown S, Jaffer A, Feeney K, Richardson G, Joseph JP, Argus L, Sara X, Antypas A, de Andres Crespo M, Daly E, Abraha S. Medical student engagement with surgery and research during the COVID-19 pandemic: Supporting the future workforce for post-pandemic surgical recovery. Int J Surg. 2021 Nov; 95:106105. PMID: 34597820.
      View in: PubMed
    16. Penthala NR, Balasubramaniam M, Dachavaram SS, Morris EJ, Bhat-Nakshatri P, Ponder J, Jordan CT, Nakshatri H, Crooks PA. Antitumor properties of novel sesquiterpene lactone analogs as NF?B inhibitors that bind to the IKK? ubiquitin-like domain (ULD). Eur J Med Chem. 2021 Nov 15; 224:113675. PMID: 34229108.
      View in: PubMed
    17. Chavez JS, Rabe JL, Loeffler D, Higa KC, Hernandez G, Mills TS, Ahmed N, Gessner RL, Ke Z, Idler BM, Ni?o KE, Kim H, Myers JR, Stevens BM, Davizon-Castillo P, Jordan CT, Nakajima H, Ashton J, Welner RS, Schroeder T, DeGregori J, Pietras EM. PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress. J Exp Med. 2021 06 07; 218(6). PMID: 33857288.
      View in: PubMed
    18. Alwaseem H, Giovani S, Crotti M, Welle K, Jordan CT, Ghaemmaghami S, Fasan R. Comprehensive Structure-Activity Profiling of Micheliolide and its Targeted Proteome in Leukemia Cells via Probe-Guided Late-Stage C-H Functionalization. ACS Cent Sci. 2021 May 26; 7(5):841-857. PMID: 34079900.
      View in: PubMed
    19. Jones CL, Inguva A, Jordan CT. Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors. Cell Stem Cell. 2021 03 04; 28(3):378-393. PMID: 33667359.
      View in: PubMed
    20. Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax?+?azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2021 06; 62(6):1466-1473. PMID: 33375853.
      View in: PubMed
    21. Stevens BM, O'Brien C, Jordan CT, Jones CL. Enriching for human acute myeloid leukemia stem cells using reactive oxygen species-based cell sorting. STAR Protoc. 2021 03 19; 2(1):100248. PMID: 33437968.
      View in: PubMed
    22. Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight. 2020 12 03; 5(23). PMID: 33268596.
      View in: PubMed
    23. Pollyea DA, Kim HM, Stevens BM, Lee FF, Harris C, Hedin BR, Knapp JR, O'Connor BP, Jordan CT, Pietras EM, Tan AC, Alper S. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells. J Leukoc Biol. 2021 07; 110(1):197-205. PMID: 33155727.
      View in: PubMed
    24. Walker ZJ, Idler BM, Davis LN, Stevens BM, VanWyngarden MJ, Ohlstrom D, Bearrows SC, Hammes A, Smith CA, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clin Cancer Res. 2021 02 01; 27(3):819-830. PMID: 33109736.
      View in: PubMed
    25. Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D'Alessandro A, Winters A, Krug A, Abbott D, Goosman M, Pei S, Ye H, Gillen AE, Becker MW, Savona MR, Smith C, Jordan CT. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020 12; 1(12):1176-1187. PMID: 33884374.
      View in: PubMed
    26. Ye H, Minhajuddin M, Krug A, Pei S, Chou CH, Culp-Hill R, Ponder J, De Bloois E, Schniedewind B, Amaya ML, Inguva A, Stevens BM, Pollyea DA, Christians U, Grimes HL, D'Alessandro A, Jordan CT. The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG. Cancer Discov. 2021 02; 11(2):500-519. PMID: 33028621.
      View in: PubMed
    27. Fisher MH, Kirkpatrick GD, Stevens B, Jones C, Callaghan M, Rajpurkar M, Fulbright J, Cooper MA, Rowley J, Porter CC, Gutierrez-Hartmann A, Jones K, Jordan C, Pietras EM, Di Paola J. ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. JCI Insight. 2020 09 17; 5(18). PMID: 32841218.
      View in: PubMed
    28. Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, Minhajuddin M, Abbott D, Becker MW, DeGregori J, Smith CA, D'Alessandro A, Jordan CT. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell. 2020 11 05; 27(5):748-764.e4. PMID: 32822582.
      View in: PubMed
    29. Yang C, Chen F, Ren P, Lofchy L, Wan C, Shen J, Wang G, Gaikwad H, Ponder J, Jordan CT, Scheinman R, Simberg D. Delivery of a model lipophilic membrane cargo to bone marrow via cell-derived microparticles. J Control Release. 2020 10 10; 326:324-334. PMID: 32682903.
      View in: PubMed
    30. Walker ZJ, VanWyngarden MJ, Stevens BM, Abbott D, Hammes A, Langou?t-Astrie C, Smith CA, Palmer BE, Forsberg PA, Mark TM, Jordan CT, Sherbenou DW. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. Blood Adv. 2020 04 28; 4(8):1628-1639. PMID: 32311014.
      View in: PubMed
    31. Matheson CJ, Casalvieri KA, Backos DS, Minhajuddin M, Jordan CT, Reigan P. Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors. Eur J Med Chem. 2020 Jul 01; 197:112316. PMID: 32334266.
      View in: PubMed
    32. Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020 04; 10(4):536-551. PMID: 31974170.
      View in: PubMed
    33. Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, Pollyea DA. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019 10 22; 3(20):2911-2919. PMID: 31648312.
      View in: PubMed
    34. Jordan CT. Can we selectively target AML stem cells? Best Pract Res Clin Haematol. 2019 12; 32(4):101100. PMID: 31779978.
      View in: PubMed
    35. Rosser J, Bachmann B, Jordan C, Ribitsch I, Haltmayer E, Gueltekin S, Junttila S, Galik B, Gyenesei A, Haddadi B, Harasek M, Egerbacher M, Ertl P, Jenner F. Microfluidic nutrient gradient-based three-dimensional chondrocyte culture-on-a-chip as an in vitro equine arthritis model. Mater Today Bio. 2019 Sep; 4:100023. PMID: 32159153.
      View in: PubMed
    36. Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T cells for the treatment of myelodysplastic syndrome. Exp Hematol. 2019 06; 74:52-63.e3. PMID: 31136781.
      View in: PubMed
    37. Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz JA, Pei S, Gustafson A, Khan N, DeGregori J, Pollyea DA, Jordan CT. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood. 2019 07 25; 134(4):389-394. PMID: 31101624.
      View in: PubMed
    38. Hernandez G, Mills TS, Rabe JL, Chavez JS, Kuldanek S, Kirkpatrick G, Noetzli L, Jubair WK, Zanche M, Myers JR, Stevens BM, Fleenor CJ, Adane B, Dinarello CA, Ashton J, Jordan CT, Di Paola J, Hagman JR, Holers VM, Kuhn KA, Pietras EM. Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. Haematologica. 2020 03; 105(3):585-597. PMID: 31101752.
      View in: PubMed
    39. Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, Jordan CT, Smith C, Pollyea DA. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Leuk Res. 2019 06; 81:43-49. PMID: 31009835.
      View in: PubMed
    40. Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, Jones CL, D'Alessandro A, Reisz JA, Zaberezhnyy V, Gasparetto M, Ho TC, Kelly KK, Myers JR, Ashton JM, Siegenthaler J, Kume T, Campbell EL, Pollyea DA, Becker MW, Jordan CT. The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. Cell Rep. 2019 04 02; 27(1):238-254.e6. PMID: 30943405.
      View in: PubMed
    41. Gregory MA, Nemkov T, Park HJ, Zaberezhnyy V, Gehrke S, Adane B, Jordan CT, Hansen KC, D'Alessandro A, DeGregori J. Targeting Glutamine Metabolism and Redox State for Leukemia Therapy. Clin Cancer Res. 2019 07 01; 25(13):4079-4090. PMID: 30940653.
      View in: PubMed
    42. Pollyea DA, Harris C, Rabe JL, Hedin BR, De Arras L, Katz S, Wheeler E, Bejar R, Walter MJ, Jordan CT, Pietras EM, Alper S. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. Haematologica. 2019 09; 104(9):e388-e392. PMID: 30846499.
      View in: PubMed
    43. Pollyea DA, Jordan CT. Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective? Curr Opin Hematol. 2019 03; 26(2):71-76. PMID: 30652974.
      View in: PubMed
    44. Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, Jordan CT. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 2019 Feb 11; 35(2):333-335. PMID: 30753831.
      View in: PubMed
    45. Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith C, Jordan CT. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018 12; 24(12):1859-1866. PMID: 30420752.
      View in: PubMed
    46. Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, Jordan CT. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 2018 11 12; 34(5):724-740.e4. PMID: 30423294.
      View in: PubMed
    47. Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight. 2018 11 02; 3(21). PMID: 30385715.
      View in: PubMed
    48. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018 10; 562(7728):526-531. PMID: 30333627.
      View in: PubMed
    49. Ye H, Adane B, Khan N, Alexeev E, Nusbacher N, Minhajuddin M, Stevens BM, Winters AC, Lin X, Ashton JM, Purev E, Xing L, Pollyea DA, Lozupone CA, Serkova NJ, Colgan SP, Jordan CT. Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. Cancer Cell. 2018 10 08; 34(4):659-673.e6. PMID: 30270124.
      View in: PubMed
    50. Stevens BM, Khan N, D'Alessandro A, Nemkov T, Winters A, Jones CL, Zhang W, Pollyea DA, Jordan CT. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nat Commun. 2018 09 12; 9(1):3694. PMID: 30209285.
      View in: PubMed
    51. Janganati V, Ponder J, Balasubramaniam M, Bhat-Nakshatri P, Bar EE, Nakshatri H, Jordan CT, Crooks PA. MMB triazole analogs are potent NF-?B inhibitors and anti-cancer agents against both hematological and solid tumor cells. Eur J Med Chem. 2018 Sep 05; 157:562-581. PMID: 30121494.
      View in: PubMed
    52. Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, Pollyea DA, Smith CA, Jordan CT. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell. 2018 Jul 05; 23(1):86-100.e6. PMID: 29910151.
      View in: PubMed
    53. Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, Jordan CT, Venkataraman S, Vibhakar R, Porter CC. A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. Mol Cancer Ther. 2017 10; 16(10):2058-2068. PMID: 28655785.
      View in: PubMed
    54. Bommagani S, Ponder J, Penthala NR, Janganati V, Jordan CT, Borrelli MJ, Crooks PA. Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells. Eur J Med Chem. 2017 Aug 18; 136:393-405. PMID: 28525840.
      View in: PubMed
    55. Janganati V, Ponder J, Thakkar S, Jordan CT, Crooks PA. Succinamide derivatives of melampomagnolide B and their anti-cancer activities. Bioorg Med Chem. 2017 07 15; 25(14):3694-3705. PMID: 28545815.
      View in: PubMed
    56. Gasparetto M, Pei S, Minhajuddin M, Khan N, Pollyea DA, Myers JR, Ashton JM, Becker MW, Vasiliou V, Humphries KR, Jordan CT, Smith CA. Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. Haematologica. 2017 06; 102(6):1054-1065. PMID: 28280079.
      View in: PubMed
    57. Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017 03 23; 129(12):1627-1635. PMID: 28159738.
      View in: PubMed
    58. Albayati ZAF, Janganati V, Chen Z, Ponder J, Breen PJ, Jordan CT, Crooks PA. Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia. Bioorg Med Chem. 2017 02 01; 25(3):1235-1241. PMID: 28049618.
      View in: PubMed
    59. Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT. Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells. J Biol Chem. 2016 11 25; 291(48):25280. PMID: 27888238.
      View in: PubMed
    60. Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, DeGregori J. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6669-E6678. PMID: 27791036.
      View in: PubMed
    61. Li B, Zhao W, Zhang X, Wang J, Luo X, Baker SD, Jordan CT, Dong Y. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. Bioorg Med Chem. 2016 11 15; 24(22):5855-5860. PMID: 27687970.
      View in: PubMed
    62. Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT. Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. J Biol Chem. 2016 Oct 14; 291(42):21984-22000. PMID: 27573247.
      View in: PubMed
    63. Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 2016 09 29; 128(13):1671-8. PMID: 27421961.
      View in: PubMed
    64. Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, Klemm DJ, Woolthuis CM, Stranahan AW, Park CY, Jordan CT. Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. Cell Stem Cell. 2016 07 07; 19(1):23-37. PMID: 27374788.
      View in: PubMed
    65. Tyagi V, Alwaseem H, O'Dwyer KM, Ponder J, Li QY, Jordan CT, Fasan R. Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs. Bioorg Med Chem. 2016 09 01; 24(17):3876-3886. PMID: 27396927.
      View in: PubMed
    66. Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016 03 10; 2:16010. PMID: 27159408.
      View in: PubMed
    67. Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar; 1(3):e85630. PMID: 27158668.
      View in: PubMed
    68. Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. J Clin Invest. 2016 Apr 01; 126(4):1438-50. PMID: 26927674.
      View in: PubMed
    69. Smith KS, Yadav VK, Pei S, Pollyea DA, Jordan CT, De S. SomVarIUS: somatic variant identification from unpaired tissue samples. Bioinformatics. 2016 03 15; 32(6):808-13. PMID: 26589277.
      View in: PubMed
    70. Janganati V, Ponder J, Jordan CT, Borrelli MJ, Penthala NR, Crooks PA. Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells. J Med Chem. 2015 Nov 25; 58(22):8896-906. PMID: 26540463.
      View in: PubMed
    71. Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee CK, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, Pollyea DA. Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. Leuk Lymphoma. 2016; 57(4):927-34. PMID: 26389776.
      View in: PubMed
    72. Pulvino M, Chen L, Oleksyn D, Li J, Compitello G, Rossi R, Spence S, Balakrishnan V, Jordan C, Poligone B, Casulo C, Burack R, Shapiro JL, Bernstein S, Friedberg JW, Deshaies RJ, Land H, Zhao J. Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. Oncotarget. 2015 Jun 20; 6(17):14796-813. PMID: 26142707.
      View in: PubMed
    73. Hyrien O, Yanev NM, Jordan CT. A test of homogeneity for age-dependent branching processes with immigration. Electron J Stat. 2015; 9(1):898-925. PMID: 27134694.
      View in: PubMed
    74. Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, Levy JM, Pollyea DA, Jordan CT, Yan P, Frankhouser D, Nicolet D, Maharry K, Marcucci G, Choi KS, Cho H, Thorburn A, Kim YS. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015 Jun; 25(6):707-25. PMID: 25952668.
      View in: PubMed
    75. Connelly J, Pilch N, Oliver M, Jordan C, Fleming J, Meadows H, Baliga P, Nadig S, Twombley K, Shatat I, Taber D. Prediction of medication non-adherence and associated outcomes in pediatric kidney transplant recipients. Pediatr Transplant. 2015 Aug; 19(5):555-62. PMID: 25917112.
      View in: PubMed
    76. Baranello MP, Bauer L, Jordan CT, Benoit DSW. Micelle Delivery of Parthenolide to Acute Myeloid Leukemia Cells. Cell Mol Bioeng. 2015 Sep; 8(3):455-470. PMID: 29552235.
      View in: PubMed
    77. Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, Jordan CT, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, Earp HS, Graham DK. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget. 2015 Mar 30; 6(9):6722-36. PMID: 25762638.
      View in: PubMed
    78. Smith C, Gasparetto M, Jordan C, Pollyea DA, Vasiliou V. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. Adv Exp Med Biol. 2015; 815:349-59. PMID: 25427917.
      View in: PubMed
    79. Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, DeGregori J. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res. 2015 Mar 15; 21(6):1360-72. PMID: 25547679.
      View in: PubMed
    80. Kim SW, Schifano M, Oleksyn D, Jordan CT, Ryan D, Insel R, Zhao J, Chen L. Protein kinase C-associated kinase regulates NF-?B activation through inducing IKK activation. Int J Oncol. 2014 Oct; 45(4):1707-14. PMID: 25096806.
      View in: PubMed
    81. Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014 Aug; 99(8):1277-84. PMID: 25082785.
      View in: PubMed
    82. Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Mol Cancer Ther. 2014 Aug; 13(8):1979-90. PMID: 24934933.
      View in: PubMed
    83. Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, Miller WH, Borden KL. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 2014 Jul 03; 511(7507):90-3. PMID: 24870236.
      View in: PubMed
    84. Gandhi UH, Kaushal N, Hegde S, Finch ER, Kudva AK, Kennett MJ, Jordan CT, Paulson RF, Prabhu KS. Selenium suppresses leukemia through the action of endogenous eicosanoids. Cancer Res. 2014 Jul 15; 74(14):3890-901. PMID: 24872387.
      View in: PubMed
    85. Smith C, Gasparetto M, Humphries K, Pollyea DA, Vasiliou V, Jordan CT. Aldehyde dehydrogenases in acute myeloid leukemia. Ann N Y Acad Sci. 2014 Mar; 1310:58-68. PMID: 24641679.
      View in: PubMed
    86. Callahan KP, Minhajuddin M, Corbett C, Lagadinou ED, Rossi RM, Grose V, Balys MM, Pan L, Jacob S, Frontier A, Grever MR, Lucas DM, Kinghorn AD, Liesveld JL, Becker MW, Jordan CT. Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. Leukemia. 2014 Oct; 28(10):1960-8. PMID: 24577530.
      View in: PubMed
    87. Liu S, Miriyala S, Keaton MA, Jordan CT, Wiedl C, Clair DK, Moscow JA. Metabolic effects of acute thiamine depletion are reversed by rapamycin in breast and leukemia cells. PLoS One. 2014; 9(1):e85702. PMID: 24454921.
      View in: PubMed
    88. Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, Gebelein B, Grimes HL. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest. 2014 Jan; 124(1):222-36. PMID: 24334453.
      View in: PubMed
    89. Kolev JN, O'Dwyer KM, Jordan CT, Fasan R. Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization. ACS Chem Biol. 2014 Jan 17; 9(1):164-73. PMID: 24206617.
      View in: PubMed
    90. Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Liesveld JL, O'Dwyer KM, Li Z, Shi L, Greninger P, Settleman J, Benes C, Hagen FK, Munger J, Crooks PA, Becker MW, Jordan CT. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem. 2013 Nov 22; 288(47):33542-33558. PMID: 24089526.
      View in: PubMed
    91. Howard DS, Liesveld J, Phillips GL, Hayslip J, Weiss H, Jordan CT, Guzman ML. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. Leuk Res. 2013 Nov; 37(11):1502-8. PMID: 24075534.
      View in: PubMed
    92. Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL. A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leuk Res. 2013 Dec; 37(12):1622-7. PMID: 24138944.
      View in: PubMed
    93. Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, J?r?s M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, Fujisaki J, Silberstein L, Alexe G, Al-Hajj MA, Shelton CA, Armstrong SA, Root DE, Scadden DT, Hynes RO, Mukherjee S, Stegmaier K, Jordan CT, Ebert BL. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 2013 Jul 08; 24(1):45-58. PMID: 23770013.
      View in: PubMed
    94. Sen S, Hassane DC, Corbett C, Becker MW, Jordan CT, Guzman ML. Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Exp Hematol. 2013 Sep; 41(9):799-807.e4. PMID: 23660068.
      View in: PubMed
    95. Nielsen TH, Johnson N, Garnier N, Kwan S, Yao L, Cocolakis E, H?bert J, Morgan RA, Paquet E, Callahan KP, Jordan CT, Assouline S, Miller WH, Mann KK. Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient. Front Pharmacol. 2013; 4:9. PMID: 23408639.
      View in: PubMed
    96. Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O'Dwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013 Mar 07; 12(3):329-41. PMID: 23333149.
      View in: PubMed
    97. Pei S, Jordan CT. How close are we to targeting the leukemia stem cell? Best Pract Res Clin Haematol. 2012 Dec; 25(4):415-8. PMID: 23200537.
      View in: PubMed
    98. Sampson ER, McMurray HR, Hassane DC, Newman L, Salzman P, Jordan CT, Land H. Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery. Oncogene. 2013 Aug 15; 32(33):3809-18. PMID: 22964631.
      View in: PubMed
    99. Ashton JM, Balys M, Neering SJ, Hassane DC, Cowley G, Root DE, Miller PG, Ebert BL, McMurray HR, Land H, Jordan CT. Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell. 2012 Sep 07; 11(3):359-72. PMID: 22863534.
      View in: PubMed
    100. Zhao C, Xiu Y, Ashton J, Xing L, Morita Y, Jordan CT, Boyce BF. Noncanonical NF-?B signaling regulates hematopoietic stem cell self-renewal and microenvironment interactions. Stem Cells. 2012 Apr; 30(4):709-18. PMID: 22290873.
      View in: PubMed
    101. Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, Calvi LM. Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood. 2012 Jan 12; 119(2):540-50. PMID: 21957195.
      View in: PubMed
    102. Becker MW, Jordan CT. Leukemia stemness signatures step toward the clinic. Cell Stem Cell. 2011 Sep 02; 9(3):185-6. PMID: 21885015.
      View in: PubMed
    103. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One. 2011; 6(8):e23108. PMID: 21853076.
      View in: PubMed
    104. Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Invest. 2011 Aug; 29(7):439-50. PMID: 21740082.
      View in: PubMed
    105. Nasim S, Guzman ML, Jordan CT, Crooks PA. Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture. Bioorg Med Chem Lett. 2011 Aug 15; 21(16):4879-83. PMID: 21757349.
      View in: PubMed
    106. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011 Feb 10; 29(5):591-9. PMID: 21220598.
      View in: PubMed
    107. Becker MW, Jordan CT. Leukemia stem cells in 2010: current understanding and future directions. Blood Rev. 2011 Mar; 25(2):75-81. PMID: 21216511.
      View in: PubMed
    108. Nasim S, Pei S, Hagen FK, Jordan CT, Crooks PA. Melampomagnolide B: a new antileukemic sesquiterpene. Bioorg Med Chem. 2011 Feb 15; 19(4):1515-9. PMID: 21273084.
      View in: PubMed
    109. Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 2010 Dec 23; 116(26):5983-90. PMID: 20889920.
      View in: PubMed
    110. Silvers CR, Williams K, Salamone L, Huang J, Jordan CT, Zhou H, Palapattu GS. A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors. Prostate. 2010 Sep 15; 70(13):1379-87. PMID: 20687210.
      View in: PubMed
    111. Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, Dent P, Jordan CT, Grant S. The NF (Nuclear factor)-?B inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol. 2010 Oct; 151(1):70-83. PMID: 20701602.
      View in: PubMed
    112. Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim SH, Kim DW, Chuah C, Oehler VG, Radich JP, Jordan CT, Reya T. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 2010 Aug 05; 466(7307):765-8. PMID: 20639863.
      View in: PubMed
    113. Jordan CT. Targeting myeloid leukemia stem cells. Sci Transl Med. 2010 May 12; 2(31):31ps21. PMID: 20463365.
      View in: PubMed
    114. Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant. 2010 Jun; 16(6):709-28. PMID: 20227509.
      View in: PubMed
    115. Skalska J, Brookes PS, Nadtochiy SM, Hilchey SP, Jordan CT, Guzman ML, Maggirwar SB, Briehl MM, Bernstein SH. Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide. PLoS One. 2009 Dec 02; 4(12):e8115. PMID: 19956548.
      View in: PubMed
    116. Frisch BJ, Porter RL, Gigliotti BJ, Olm-Shipman AJ, Weber JM, O'Keefe RJ, Jordan CT, Calvi LM. In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. Blood. 2009 Nov 05; 114(19):4054-63. PMID: 19726721.
      View in: PubMed
    117. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009 Jun 26; 324(5935):1670-3. PMID: 19556499.
      View in: PubMed
    118. Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y. Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. Int J Radiat Oncol Biol Phys. 2009 Aug 01; 74(5):1580-91. PMID: 19540073.
      View in: PubMed
    119. Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett. 2009 Aug 01; 19(15):4346-9. PMID: 19505822.
      View in: PubMed
    120. Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Guzman ML, Sen S, Yonkovich S, Liu S, Zhan X, Tomasevic N, Zhou C, Gros D, Jordan CT, Gotlib J, Hsi ED, Abo A. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Leukemia. 2009 Sep; 23(9):1587-97. PMID: 19440216.
      View in: PubMed
    121. Guzman ML, Jordan CT. Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology. Cancer Cell. 2009 Apr 07; 15(4):252-4. PMID: 19345324.
      View in: PubMed
    122. Jordan CT. Cancer stem cells: controversial or just misunderstood? Cell Stem Cell. 2009 Mar 06; 4(3):203-5. PMID: 19265659.
      View in: PubMed
    123. Hewamana S, Lin TT, Jenkins C, Burnett AK, Jordan CT, Fegan C, Brennan P, Rowntree C, Pepper C. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res. 2008 Dec 15; 14(24):8102-11. PMID: 19088025.
      View in: PubMed
    124. Jordan CT. Can we finally target the leukemic stem cells? Best Pract Res Clin Haematol. 2008 Dec; 21(4):615-20. PMID: 19041600.
      View in: PubMed
    125. Wang PY, Young F, Chen CY, Stevens BM, Neering SJ, Rossi RM, Bushnell T, Kuzin I, Heinrich D, Bottaro A, Jordan CT. The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene. Blood. 2008 Nov 15; 112(10):4184-92. PMID: 18755985.
      View in: PubMed
    126. Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol. 2008 Oct; 19(10):1759-64. PMID: 18504251.
      View in: PubMed
    127. Young FM, Campbell A, Emo KL, Jansson J, Wang PY, Jordan CT, Mullen CA. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells. Biol Blood Marrow Transplant. 2008 Jun; 14(6):622-30. PMID: 18489987.
      View in: PubMed
    128. Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 2008 Jun 15; 111(12):5654-62. PMID: 18305216.
      View in: PubMed
    129. Mao G, Yuan F, Absher K, Jennings CD, Howard DS, Jordan CT, Gu L. Preferential loss of mismatch repair function in refractory and relapsed acute myeloid leukemia: potential contribution to AML progression. Cell Res. 2008 Feb; 18(2):281-9. PMID: 18227862.
      View in: PubMed
    130. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 2008 May 01; 111(9):4681-9. PMID: 18227347.
      View in: PubMed
    131. Kim SW, Oleksyn DW, Rossi RM, Jordan CT, Sanz I, Chen L, Zhao J. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells. Blood. 2008 Feb 01; 111(3):1644-53. PMID: 18025152.
      View in: PubMed
    132. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007 Dec 15; 110(13):4427-35. PMID: 17804695.
      View in: PubMed
    133. Guzman ML, Li X, Corbett CA, Rossi RM, Bushnell T, Liesveld JL, H?bert J, Young F, Jordan CT. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood. 2007 Dec 15; 110(13):4436-44. PMID: 17785584.
      View in: PubMed
    134. Neering SJ, Bushnell T, Sozer S, Ashton J, Rossi RM, Wang PY, Bell DR, Heinrich D, Bottaro A, Jordan CT. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood. 2007 Oct 01; 110(7):2578-85. PMID: 17601986.
      View in: PubMed
    135. Jordan CT. The leukemic stem cell. Best Pract Res Clin Haematol. 2007 Mar; 20(1):13-8. PMID: 17336250.
      View in: PubMed
    136. Bostrom MA, Boyanovsky BB, Jordan CT, Wadsworth MP, Taatjes DJ, de Beer FC, Webb NR. Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol. 2007 Mar; 27(3):600-6. PMID: 17204667.
      View in: PubMed
    137. Jordan CT. Searching for leukemia stem cells--not yet the end of the road? Cancer Cell. 2006 Oct; 10(4):253-4. PMID: 17045202.
      View in: PubMed
    138. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006 Sep 21; 355(12):1253-61. PMID: 16990388.
      View in: PubMed
    139. Weber JM, Forsythe SR, Christianson CA, Frisch BJ, Gigliotti BJ, Jordan CT, Milner LA, Guzman ML, Calvi LM. Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. Bone. 2006 Sep; 39(3):485-93. PMID: 16647886.
      View in: PubMed
    140. Guzman ML, Jordan CT. Feverfew: weeding out the root of leukaemia. Expert Opin Biol Ther. 2005 Sep; 5(9):1147-52. PMID: 16120045.
      View in: PubMed
    141. Jordan CT. Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biology. Nat Clin Pract Oncol. 2005 May; 2(5):224-5. PMID: 16264940.
      View in: PubMed
    142. Jordan CT. The potential of targeting malignant stem cells as a treatment for leukemia. Future Oncol. 2005 Apr; 1(2):205-7. PMID: 16555992.
      View in: PubMed
    143. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005 Jun 01; 105(11):4163-9. PMID: 15687234.
      View in: PubMed
    144. Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Mol Cell Biol. 2005 Feb; 25(3):1100-12. PMID: 15657436.
      View in: PubMed
    145. Jordan CT. Cancer stem cell biology: from leukemia to solid tumors. Curr Opin Cell Biol. 2004 Dec; 16(6):708-12. PMID: 15530785.
      View in: PubMed
    146. Jordan CT. A new approach to treatment of acute myelogenous leukemia using targeted therapy in combination with standard chemotherapy. Leuk Res. 2004 Nov; 28(11):1121-2. PMID: 15380333.
      View in: PubMed
    147. Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene. 2004 Sep 20; 23(43):7178-87. PMID: 15378078.
      View in: PubMed
    148. Goodrum F, Jordan CT, Terhune SS, High K, Shenk T. Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations. Blood. 2004 Aug 01; 104(3):687-95. PMID: 15090458.
      View in: PubMed
    149. Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control. 2004 Mar-Apr; 11(2):97-104. PMID: 15024346.
      View in: PubMed
    150. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program. 2004; 80-97. PMID: 15561678.
      View in: PubMed
    151. Liesveld JL, Jordan CT, Phillips GL. The hematopoietic stem cell in myelodysplasia. Stem Cells. 2004; 22(4):590-9. PMID: 15277704.
      View in: PubMed
    152. Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, Borden KL. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol. 2003 Dec; 23(24):8992-9002. PMID: 14645512.
      View in: PubMed
    153. Srour EF, Jordan CT. Isolation and characterization of primitive hematopoietic cells based on their position in the cell cycle. Methods Mol Med. 2002; 63:93-111. PMID: 21437802.
      View in: PubMed
    154. Jordan CT, Vanin EF, Marini FC. The use of adenoviral vectors for genetic manipulation and analysis of primitive hematopoietic cells. Curr Gene Ther. 2001 Sep; 1(3):257-65. PMID: 12109141.
      View in: PubMed
    155. Guzman ML, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Phillips GL, Jordan CT. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood. 2001 Apr 01; 97(7):2177-9. PMID: 11264190.
      View in: PubMed
    156. Lemischka IR, Jordan CT. The return of clonal marking sheds new light on human hematopoietic stem cells. Nat Immunol. 2001 Jan; 2(1):11-2. PMID: 11135569.
      View in: PubMed
    157. Evans ME, Jordan CT, Chang SM, Conrad C, Gerberding JL, Kaufman HL, Mayhall CG, Nolta JA, Pilaro AM, Sullivan S, Weber DJ, Wivel NA. Clinical infection control in gene therapy: a multidisciplinary conference. Infect Control Hosp Epidemiol. 2000 Oct; 21(10):659-73. PMID: 11083185.
      View in: PubMed
    158. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000 Oct; 14(10):1777-84. PMID: 11021753.
      View in: PubMed
    159. Howard DS, Rizzierri DA, Grimes B, Upchurch D, Phillips GL, Stewart AK, Yannelli JR, Jordan CT. Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer. Leukemia. 1999 Oct; 13(10):1608-16. PMID: 10516763.
      View in: PubMed
    160. Rosenzweig M, MacVittie TJ, Harper D, Hempel D, Glickman RL, Johnson RP, Farese AM, Whiting-Theobald N, Linton GF, Yamasaki G, Jordan CT, Malech HL. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood. 1999 Oct 01; 94(7):2271-86. PMID: 10498599.
      View in: PubMed
    161. Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, Kohn DB, Crooks GM. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):2988-93. PMID: 10077624.
      View in: PubMed
    162. Jordan CT, Van Zant G. Recent progress in identifying genes regulating hematopoietic stem cell function and fate. Curr Opin Cell Biol. 1998 Dec; 10(6):716-20. PMID: 9914177.
      View in: PubMed
    163. Bregni M, Shammah S, Malaffo F, Di Nicola M, Milanesi M, Magni M, Matteucci P, Ravagnani F, Jordan CT, Siena S, Gianni AM. Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. Gene Ther. 1998 Apr; 5(4):465-72. PMID: 9614570.
      View in: PubMed
    164. Harrison DE, Zhong RK, Jordan CT, Lemischka IR, Astle CM. Relative to adult marrow, fetal liver repopulates nearly five times more effectively long-term than short-term. Exp Hematol. 1997 Apr; 25(4):293-7. PMID: 9131003.
      View in: PubMed
    165. Orlic D, Girard LJ, Anderson SM, Do BK, Seidel NE, Jordan CT, Bodine DM. Transduction efficiency of cell lines and hematopoietic stem cells correlates with retrovirus receptor mRNA levels. Stem Cells. 1997; 15 Suppl 1:23-8; discussion 28-9. PMID: 9368321.
      View in: PubMed
    166. Orlic D, Girard LJ, Jordan CT, Anderson SM, Cline AP, Bodine DM. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proc Natl Acad Sci U S A. 1996 Oct 01; 93(20):11097-102. PMID: 8855315.
      View in: PubMed
    167. Jordan CT, Yamasaki G, Minamoto D. High-resolution cell cycle analysis of defined phenotypic subsets within primitive human hematopoietic cell populations. Exp Hematol. 1996 Sep; 24(11):1347-55. PMID: 8862447.
      View in: PubMed
    168. Neering SJ, Hardy SF, Minamoto D, Spratt SK, Jordan CT. Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors. Blood. 1996 Aug 15; 88(4):1147-55. PMID: 8695831.
      View in: PubMed
    169. Jordan CT, Astle CM, Zawadzki J, Mackarehtschian K, Lemischka IR, Harrison DE. Long-term repopulating abilities of enriched fetal liver stem cells measured by competitive repopulation. Exp Hematol. 1995 Aug; 23(9):1011-5. PMID: 7635180.
      View in: PubMed
    170. Zeigler FC, Bennett BD, Jordan CT, Spencer SD, Baumhueter S, Carroll KJ, Hooley J, Bauer K, Matthews W. Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells. Blood. 1994 Oct 15; 84(8):2422-30. PMID: 7919361.
      View in: PubMed
    171. Harrison DE, Jordan CT, Zhong RK, Astle CM. Primitive hemopoietic stem cells: direct assay of most productive populations by competitive repopulation with simple binomial, correlation and covariance calculations. Exp Hematol. 1993 Feb; 21(2):206-19. PMID: 8425559.
      View in: PubMed
    172. Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci U S A. 1991 Oct 15; 88(20):9026-30. PMID: 1717995.
      View in: PubMed
    173. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 1991 Jun 28; 65(7):1143-52. PMID: 1648448.
      View in: PubMed
    174. Jordan CT, McKearn JP, Lemischka IR. Cellular and developmental properties of fetal hematopoietic stem cells. Cell. 1990 Jun 15; 61(6):953-63. PMID: 1972037.
      View in: PubMed
    175. Jordan CT, Lemischka IR. Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes Dev. 1990 Feb; 4(2):220-32. PMID: 1970972.
      View in: PubMed
    Jordan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (662) concept(s)
    _
    Co-Authors Expand Description
    See all (61) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)